Form 4: Belite Bio CSO Nathan Mata Sells Shares via 10b5-1 Plan

Chief Scientific Officer Nathan L. Mata sold 1,002 American depositary shares of Belite Bio, Inc. on April 23, 2026, pursuant to a pre-arranged trading plan.

Summary

• Nathan L. Mata, Chief Scientific Officer of Belite Bio, Inc., executed a series of sales of American depositary shares (ADS) on April 23, 2026.
• A total of 1,002 shares were sold across multiple transactions at weighted average prices ranging from $164.47 to $169.56.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2025.
• Following these transactions, the reporting person retains beneficial ownership of 9,666 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-planned 10b5-1 arrangement, which is standard practice for executive financial planning.

Positives

• The sales were executed under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without concerns regarding non-public information.

Negatives

• The sale represents a reduction in the insider's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived by the market as a lack of confidence in future share price appreciation, though this was a planned divestment.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine corporate governance practice in the biotechnology sector, allowing executives to diversify holdings while maintaining compliance with SEC regulations.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for biotech executives to manage equity compensation and avoid allegations of insider trading.

Stakeholder Impact

• Minimal impact expected as the transaction was pre-planned and represents a small portion of the insider's holdings.

Key Dates

Keywords

Belite Bio, BLTE, Insider Trading, Form 4, Chief Scientific Officer, Rule 10b5-1